Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Development Process of a Clinical Decision Support System for Empiric Antibiotic Therapies in Patients With Sepsis: Case Study.
JMIR medical informatics·2026
Same author
Financial influences and the primacy of patient welfare - an empirical and ethical analysis in German cancer medicine.
BMC medical ethics·2026
Related Experiment Video
Updated: Jul 8, 2026
23:56
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Using disease management and market reforms to address the adverse economic effects of drug budgets and price and
Tim Schwermann1, Wolfgang Greiner, J M Graf v d Schulenburg
1Center of Health Economics and Health System Research, University of Hannover, Hannover, Germany.
Summary
Germany
Area of Science:
- Health economics
- Pharmaceutical policy
- Public health financing
Background:
- Germany dedicates a significant portion of its GDP to healthcare, primarily funded through labor taxes.
- Despite high overall spending, drug expenditure and per capita drug costs are relatively low.
- Recent years saw increased drug spending after a period of controlled budgets.
Purpose of the Study:
- To analyze governmental and market reforms aimed at controlling drug spending in Germany.
- To evaluate the impact of Germany's fragmented healthcare budgeting strategies on overall costs.
- To explore potential reforms for improving healthcare cost-effectiveness.
Main Methods:
- Descriptive analysis of German governmental drug budgeting initiatives.
- Examination of market reforms impacting pharmaceutical spending.
- System-wide analysis of healthcare cost implications of segmented budgets.
Main Results:
- Germany's drug budgeting evolved from central to regional and physician-based models, often detached from medical or economic rationale.
- Budgetary constraints in one area of healthcare can inadvertently increase total system costs.
- Various reforms, including positive lists, generic substitution, and e-health, are considered.
Conclusions:
- Germany's healthcare system suffers from significant segmentation across physician, drug, and hospital budgets.
- Cost-effectiveness evaluations are crucial for developing effective disease management guidelines.
- Financial incentives should be integrated with cost-effectiveness data to reform healthcare budgeting.